Category: Regulatory DisclosuresBy adminJuly 14, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:EGX Disclosure on BOD and shareholding structureNextNext post:Rameda notified of Anviziram, Remdesivir-Rameda vial prices by Egyptian Drug Authority, on track to market first Remdesivir-Rameda production in September 2020Related PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
